Role of osteopontin in dendritic cell shaping of immune responses

Cytokine and Growth Factor Reviews

Volumn 50, Issue , 2019, Pages 19-28

  Del Prete, Annalisa ^a,b   Scutera, Sara ^c   Sozzani, Silvano ^a   Musso, Tiziana ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Autoimmune diseases; Cancer; Dendritic cells; Mesenchymal stromal cells; Osteopontin; T cell polarization

Indexed keywords

ALPHA9BETA1 INTEGRIN; ALPHA9BETA7 INTEGRIN; ALPHAVBETA1 INTEGRIN; ALPHAVBETA5 INTEGRIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 27; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; OSTEOPONTIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PROSTAGLANDIN E2; RECEPTOR; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR; CYTOKINE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; AUTOCRINE EFFECT; BINDING SITE; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; EXPERIMENTAL ALLERGIC ENCEPHALITIS; HEPARIN BINDING DOMAIN; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; LIVER CANCER; LUNG CANCER; LYMPHOCYTE DIFFERENTIATION; MELANOMA; MESENCHYMAL STROMA CELL; MESOTHELIOMA; MULTIPLE SCLEROSIS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MESENCHYMAL STEM CELL; MOUSE;

ANIMALS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; MESENCHYMAL STEM CELLS; MICE; OSTEOPONTIN; TUMOR MICROENVIRONMENT;

EID: 85065837508     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2019.05.004     Document Type: Review

References (130)

1. Weber, G.F., The phylogeny of osteopontin-analysis of the protein sequence. Int. J. Mol. Sci., 2018, 19.
2. Franzen, A., Heinegard, D., Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 232 (1985), 715–724.
3. Senger, D.R., Wirth, D.F., Hynes, R.O., Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16 (1979), 885–893.
4. Ashkar, S., Weber, G.F., Panoutsakopoulou, V., Sanchirico, M.E., Jansson, M., Zawaideh, S., et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287 (2000), 860–864.
5. Singh, M., Ananthula, S., Milhorn, D.M., Krishnaswamy, G., Singh, K., Osteopontin: a novel inflammatory mediator of cardiovascular disease. Front Biosci 12 (2007), 214–221.
6. Rittling, S.R., Singh, R., Osteopontin in immune-mediated diseases. J. Dent. Res. 94 (2015), 1638–1645.
7. Wang, K.X., Denhardt, D.T., Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 19 (2008), 333–345.
8. Inoue, M., Shinohara, M.L., Intracellular osteopontin (iOPN) and immunity. Immunol. Res. 49 (2011), 160–172.
9. Uede, T., Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol. Int. 61 (2011), 265–280.
10. Castello, L.M., Raineri, D., Salmi, L., Clemente, N., Vaschetto, R., Quaglia, M., et al. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm., 2017, 2017, 4049098.
11. Hao, C., Cui, Y., Owen, S., Li, W., Cheng, S., Jiang, W.G., Human osteopontin: potential clinical applications in cancer (Review). Int. J. Mol. Med. 39 (2017), 1327–1337.
12. Solano-Galvez, S.G., Tovar-Torres, S.M., Tron-Gomez, M.S., Weiser-Smeke, A.E., Alvarez-Hernandez, D.A., Franyuti-Kelly, G.A., et al. Human dendritic cells: ontogeny and their subsets in health and disease. Med. Sci. Basel (Basel), 2018, 6.
13. Collin, M., Bigley, V., Human dendritic cell subsets: an update. Immunology 154 (2018), 3–20.
14. Macri, C., Pang, E.S., Patton, T., O'Keeffe, M., Dendritic cell subsets. Semin. Cell Dev. Biol. 84 (2018), 11–21.
15. Steinman, R.M., Hemmi, H., Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311 (2006), 17–58.
16. Blasius, A.L., Colonna, M., Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol. 27 (2006), 255–260.
17. Sozzani, S., Vermi, W., Del Prete, A., Facchetti, F., Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol. 31 (2010), 270–277.
18. Clayton, K., Vallejo, A.F., Davies, J., Sirvent, S., Polak, M.E., Langerhans Cells-Programmed by the epidermis. Front. Immunol., 8, 2017, 1676.
19. Eisenbarth, S.C., Dendritic cell subsets in T cell programming: location dictates function. Nat. Rev. Immunol., 2018.
20. Ethokic, J.M., Tomic, S.Z., Colic, M.J., Cross-talk between mesenchymal Stem/Stromal cells and dendritic cells. Curr. Stem Cell Res. Ther. 11 (2016), 51–65.
21. Svensson, M., Kaye, P.M., Stromal-cell regulation of dendritic-cell differentiation and function. Trends Immunol. 27 (2006), 580–587.
22. Pulendran, B., Tang, H., Denning, T.L., Division of labor, plasticity, and crosstalk between dendritic cell subsets. Curr. Opin. Immunol. 20 (2008), 61–67.
23. Kawamura, K., Iyonaga, K., Ichiyasu, H., Nagano, J., Suga, M., Sasaki, Y., Differentiation, maturation, and survival of dendritic cells by osteopontin regulation. Clin. Diagn. Lab. Immunol. 12 (2005), 206–212.
24. Schulz, G., Renkl, A.C., Seier, A., Liaw, L., Weiss, J.M., Regulated osteopontin expression by dendritic cells decisively affects their migratory capacity. J. Invest. Dermatol. 128 (2008), 2541–2544.
25. Renkl, A.C., Wussler, J., Ahrens, T., Thoma, K., Kon, S., Uede, T., et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 106 (2005), 946–955.
26. Sodek, J., Ganss, B., McKee MD. Osteopontin. Crit Rev Oral Biol Med 11 (2000), 279–303.
27. Kaleta, B., Role of osteopontin in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz) 62 (2014), 475–482.
28. Briones-Orta, M.A., Avendano-Vazquez, S.E., Aparicio-Bautista, D.I., Coombes, J.D., Weber, G.F., Syn, W.K., Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim. Biophys. Acta Rev. Cancer 1868 (2017), 93–108 A.
29. Wei, R., Wong, J.P.C., Kwok, H.F., Osteopontin – a promising biomarker for cancer therapy. J. Cancer 8 (2017), 2173–2183.
30. Gimba, E.R., Tilli, T.M., Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 331 (2013), 11–17.
31. Grassinger, J., Haylock, D.N., Storan, M.J., Haines, G.O., Williams, B., Whitty, G.A., et al. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 114 (2009), 49–59.
32. Weber, G.F., Ashkar, S., Glimcher, M.J., Cantor, H., Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271 (1996), 509–512.
33. Shao, L., Zhang, B., Wang, L., Wu, L., Kan, Q., Fan, K., MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells. Biochem. Biophys. Res. Commun. 493 (2017), 1478–1484.
34. Kon, S., Nakayama, Y., Matsumoto, N., Ito, K., Kanayama, M., Kimura, C., et al. A novel cryptic binding motif, LRSKSRSFQVSDEQY, in the C-terminal fragment of MMP-3/7-cleaved osteopontin as a novel ligand for alpha9beta1 integrin is involved in the anti-type II collagen antibody-induced arthritis. PLoS One, 9, 2014, e116210.
35. Weiss, J.M., Renkl, A.C., Maier, C.S., Kimmig, M., Liaw, L., Ahrens, T., et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J. Exp. Med. 194 (2001), 1219–1229.
36. Shao, Z., Morser, J., Leung, L.L., Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment. J. Biol. Chem. 289 (2014), 27146–27158.
37. Alissafi, T., Kourepini, E., Simoes, D.C.M., Paschalidis, N., Aggelakopoulou, M., Sparwasser, T., et al. Osteopontin promotes protective antigenic tolerance against experimental allergic airway disease. J. Immunol. 200 (2018), 1270–1282.
38. Denhardt, D.T., Noda, M., O'Regan, A.W., Pavlin, D., Berman, J.S., Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107 (2001), 1055–1061.
39. Leavenworth, J.W., Verbinnen, B., Yin, J., Huang, H., Cantor, H., A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat. Immunol. 16 (2015), 96–106.
40. Leavenworth, J.W., Verbinnen, B., Wang, Q., Shen, E., Cantor, H., Intracellular osteopontin regulates homeostasis and function of natural killer cells. Proc Natl Acad Sci U S A 112 (2015), 494–499.
41. Inoue, M., Moriwaki, Y., Arikawa, T., Chen, Y.H., Oh, Y.J., Oliver, T., et al. Cutting edge: critical role of intracellular osteopontin in antifungal innate immune responses. J. Immunol. 186 (2011), 19–23.
42. Zhao, K., Zhang, M., Zhang, L., Wang, P., Song, G., Liu, B., et al. Intracellular osteopontin stabilizes TRAF3 to positively regulate innate antiviral response. Sci. Rep., 6, 2016, 23771.
43. Kanayama, M., Xu, S., Danzaki, K., Gibson, J.R., Inoue, M., Gregory, S.G., et al. Skewing of the population balance of lymphoid and myeloid cells by secreted and intracellular osteopontin. Nat. Immunol. 18 (2017), 973–984.
44. Junaid, A., Moon, M.C., Harding, G.E., Zahradka, P., Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am. J. Physiol., Cell Physiol. 292 (2007), C919–26.
45. Kraus, L.F., Scheurmann, N., Frenzel, D.F., Tasdogan, A., Weiss, J.M., 9-cis-Retinoic acid induces a distinct regulatory dendritic cell phenotype that modulates murine delayed-type allergy. Contact Derm. 78 (2018), 41–54.
46. Blengio, F., Raggi, F., Pierobon, D., Cappello, P., Eva, A., Giovarelli, M., et al. The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. Immunobiology 218 (2013), 76–89.
47. Yang, M., Ma, C., Liu, S., Sun, J., Shao, Q., Gao, W., et al. Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology 128 (2009), e237–49.
48. Salvi, V., Scutera, S., Rossi, S., Zucca, M., Alessandria, M., Greco, D., et al. Dual regulation of osteopontin production by TLR stimulation in dendritic cells. J. Leukoc. Biol. 94 (2013), 147–158.
49. Shinohara, M.L., Lu, L., Bu, J., Werneck, M.B., Kobayashi, K.S., Glimcher, L.H., et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat. Immunol. 7 (2006), 498–506.
50. Shinohara, M.L., Kim, J.H., Garcia, V.A., Cantor, H., Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 29 (2008), 68–78.
51. Murugaiyan, G., Mittal, A., Weiner, H.L., Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc. Natl. Acad. Sci. U S A 107 (2010), 11495–11500.
52. Konno, S., Eckman, J.A., Plunkett, B., Li, X., Berman, J.S., Schroeder, J., et al. Interleukin-10 and Th2 cytokines differentially regulate osteopontin expression in human monocytes and dendritic cells. J. Interferon Cytokine Res. 26 (2006), 562–567.
53. Hulsmans, M., Sager, H.B., Roh, J.D., Valero-Munoz, M., Houstis, N.E., Iwamoto, Y., et al. Cardiac macrophages promote diastolic dysfunction. J. Exp. Med. 215 (2018), 423–440.
54. De Keijzer, S., Meddens, M.B., Torensma, R., Cambi, A., The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle. Int. J. Mol. Sci. 14 (2013), 6542–6555.
55. Kalinski, P., Regulation of immune responses by prostaglandin E2. J. Immunol. 188 (2012), 21–28.
56. Scutera, S., Salvi, V., Lorenzi, L., Piersigilli, G., Lonardi, S., Alotto, D., et al. Adaptive regulation of osteopontin production by dendritic cells through the bidirectional interaction with mesenchymal stromal cells. Front. Immunol., 9, 2018, 1207.
57. Sozzani, S., Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev. 16 (2005), 581–592.
58. Tiberio, L., Del Prete, A., Schioppa, T., Sozio, F., Bosisio, D., Sozzani, S., Chemokine and chemotactic signals in dendritic cell migration. Cell. Mol. Immunol. 15 (2018), 346–352.
59. Begum, M.D., Umemura, M., Kon, S., Yahagi, A., Hamada, S., Oshiro, K., et al. Suppression of the bacterial antigen-specific T cell response and the dendritic cell migration to the lymph nodes by osteopontin. Microbiol. Immunol. 51 (2007), 135–147.
60. Sozzani, S., Allavena, P., D'Amico, G., Luini, W., Bianchi, G., Kataura, M., et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. 161 (1998), 1083–1086.
61. Shinohara, M.L., Cantor, H., The bridge between dendritic cells and asthma. Nat. Med. 13 (2007), 536–538.
62. de Heer, H.J., Hammad, H., Soullie, T., Hijdra, D., Vos, N., Willart, M.A., et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J. Exp. Med. 200 (2004), 89–98.
63. Lambrecht, B.N., De Veerman, M., Coyle, A.J., Gutierrez-Ramos, J.C., Thielemans, K., Pauwels, R.A., Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J. Clin. Invest. 106 (2000), 551–559.
64. van Helden, M.J., Lambrecht, B.N., Dendritic cells in asthma. Curr. Opin. Immunol. 25 (2013), 745–754.
65. Xanthou, G., Alissafi, T., Semitekolou, M., Simoes, D.C., Economidou, E., Gaga, M., et al. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat. Med. 13 (2007), 570–578.
66. Frenzel, D.F., Weiss, J.M., Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev. Clin. Immunol. 7 (2011), 93–109.
67. Sato, T., Nakai, T., Tamura, N., Okamoto, S., Matsuoka, K., Sakuraba, A., et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 54 (2005), 1254–1262.
68. Seier, A.M., Renkl, A.C., Schulz, G., Uebele, T., Sindrilaru, A., Iben, S., et al. Antigen-specific induction of osteopontin contributes to the chronification of allergic contact dermatitis. Am. J. Pathol. 176 (2010), 246–258.
69. Kurokawa, M., Konno, S., Takahashi, A., Plunkett, B., Rittling, S.R., Matsui, Y., et al. Regulatory role of DC-derived osteopontin in systemic allergen sensitization. Eur. J. Immunol. 39 (2009), 3323–3330.
70. Larche, M., Akdis, C.A., Valenta, R., Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6 (2006), 761–771.
71. Cui, G., Chen, J., He, J., Lu, C., Wei, Y., Wang, L., et al. Osteopontin promotes dendritic cell maturation and function in response to HBV antigens. Drug Des. Devel. Ther. 9 (2015), 3003–3016.
72. Cella, M., Facchetti, F., Lanzavecchia, A., Colonna, M., Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat. Immunol. 1 (2000), 305–310.
73. Krug, A., Rothenfusser, S., Hornung, V., Jahrsdorfer, B., Blackwell, S., Ballas, Z.K., et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31 (2001), 2154–2163.
74. Konno, S., Kurokawa, M., Uede, T., Nishimura, M., Huang, S.K., Role of osteopontin, a multifunctional protein, in allergy and asthma. Clin. Exp. Allergy 41 (2011), 1360–1366.
75. Uchio, E., Matsuura, N., Kadonosono, K., Ohno, S., Uede, T., Tear osteopontin levels in patients with allergic conjunctival diseases. Graefes Arch. Clin. Exp. Ophthalmol. 240 (2002), 924–928.
76. Shi, L.L., Song, J., Xiong, P., Cao, P.P., Liao, B., Ma, J., et al. Disease-specific T-helper cell polarizing function of lesional dendritic cells in different types of chronic rhinosinusitis with nasal polyps. Am. J. Respir. Crit. Care Med. 190 (2014), 628–638.
77. Deckers, J., De Bosscher, K., Lambrecht, B.N., Hammad, H., Interplay between barrier epithelial cells and dendritic cells in allergic sensitization through the lung and the skin. Immunol. Rev. 278 (2017), 131–144.
78. Kim, B., Kim, T.H., Fundamental role of dendritic cells in inducing Th2 responses. Korean J. Intern. Med. 33 (2018), 483–489.
79. Nagasaka, A., Matsue, H., Matsushima, H., Aoki, R., Nakamura, Y., Kambe, N., et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur. J. Immunol. 38 (2008), 489–499.
80. Patel, D.D., Kuchroo, V.K., Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity 43 (2015), 1040–1051.
81. Awasthi, A., Carrier, Y., Peron, J.P., Bettelli, E., Kamanaka, M., Flavell, R.A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8 (2007), 1380–1389.
82. Teixeira-Coelho, M., Cruz, A., Carmona, J., Sousa, C., Ramos-Pereira, D., Saraiva, A.L., et al. TLR2 deficiency by compromising p19 (IL-23) expression limits Th 17 cell responses to Mycobacterium tuberculosis. Int. Immunol. 23 (2011), 89–96.
83. Kim, M.R., Hong, S.W., Choi, E.B., Lee, W.H., Kim, Y.S., Jeon, S.G., et al. Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses. Allergy 67 (2012), 1271–1281.
84. Hoe, E., Anderson, J., Nathanielsz, J., Toh, Z.Q., Marimla, R., Balloch, A., et al. The contrasting roles of Th17 immunity in human health and disease. Microbiol. Immunol. 61 (2017), 49–56.
85. Murugaiyan, G., Mittal, A., Weiner, H.L., Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J. Immunol. 181 (2008), 7480–7488.
86. Buback, F., Renkl, A.C., Schulz, G., Weiss, J.M., Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp. Dermatol. 18 (2009), 750–759.
87. Glitzner, E., Korosec, A., Brunner, P.M., Drobits, B., Amberg, N., Schonthaler, H.B., et al. Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Mol. Med. 6 (2014), 1312–1327.
88. Wohn, C., Ober-Blobaum, J.L., Haak, S., Pantelyushin, S., Cheong, C., Zahner, S.P., et al. Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc Natl Acad Sci U S A 110 (2013), 10723–10728.
89. Albanesi, C., Scarponi, C., Bosisio, D., Sozzani, S., Girolomoni, G., Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity 43 (2010), 215–219.
90. Chen, Y.J., Shen, J.L., Wu, C.Y., Chang, Y.T., Chen, C.M., Lee, F.Y., Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J. Am. Acad. Dermatol. 60 (2009), 225–230.
91. Keely, S., Talley, N.J., Hansbro, P.M., Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 5 (2012), 7–18.
92. Kourepini, E., Aggelakopoulou, M., Alissafi, T., Paschalidis, N., Simoes, D.C., Panoutsakopoulou, V., Osteopontin expression by CD103- dendritic cells drives intestinal inflammation. Proc Natl Acad Sci U S A 111 (2014), E856–65.
93. Shan, M., Yuan, X., Song, L.Z., Roberts, L., Zarinkamar, N., Seryshev, A., et al. Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci. Transl. Med., 4, 2012, 117ra9.
94. Ruzicka, T., Lynde, C.W., Jemec, G.B., Diepgen, T., Berth-Jones, J., Coenraads, P.J., et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br. J. Dermatol. 158 (2008), 808–817.
95. Scott, C.L., Aumeunier, A.M., Mowat, A.M., Intestinal CD103+ dendritic cells: master regulators of tolerance?. Trends Immunol. 32 (2011), 412–419.
96. Sun, C.M., Hall, J.A., Blank, R.B., Bouladoux, N., Oukka, M., Mora, J.R., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204 (2007), 1775–1785.
97. Shevde, L.A., Samant, R.S., Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 37 (2014), 131–141.
98. Icer, M.A., Gezmen-Karadag, M., The multiple functions and mechanisms of osteopontin. Clin. Biochem. 59 (2018), 17–24.
99. Zhao, H., Chen, Q., Alam, A., Cui, J., Suen, K.C., Soo, A.P., et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis., 9, 2018, 356.
100. Awad, R.M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., Breckpot, K., Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert Cancer progression. Front. Immunol., 9, 2018, 1977.
101. Clappaert, E.J., Murgaski, A., Van Damme, H., Kiss, M., Laoui, D., Diamonds in the rough: harnessing tumor-associated myeloid cells for Cancer therapy. Front. Immunol., 9, 2018, 2250.
102. Dolcetti, L., Peranzoni, E., Bronte, V., Measurement of myeloid cell immune suppressive activity. Curr. Protoc. Immunol. 91:1 (2010), 14.17.1–14.17.25 Chapter 14:Unit 14 7.
103. Rao, G., Du, L., Chen, Q., Osteopontin, a possible modulator of cancer stem cells and their malignant niche. Oncoimmunology, 2, 2013, e24169.
104. Chiodoni, C., Sangaletti, S., Colombo, M.P., Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer. J. Leukoc. Biol. 102 (2017), 287–292.
105. Kim, E.K., Jeon, I., Seo, H., Park, Y.J., Song, B., Lee, K.A., et al. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Cancer Res. 74 (2014), 6705–6716.
106. Sangaletti, S., Tripodo, C., Sandri, S., Torselli, I., Vitali, C., Ratti, C., et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 74 (2014), 4706–4719.
107. Klement, J.D., Paschall, A.V., Redd, P.S., Ibrahim, M.L., Lu, C., Yang, D., et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J. Clin. Invest. 128 (2018), 5549–5560.
108. Veglia, F., Gabrilovich, D.I., Dendritic cells in cancer: the role revisited. Curr. Opin. Immunol. 45 (2017), 43–51.
109. Conejo-Garcia, J.R., Rutkowski, M.R., Cubillos-Ruiz, J.R., State-of-the-art of regulatory dendritic cells in cancer. Pharmacol. Ther. 164 (2016), 97–104.
110. Mancino, A., Schioppa, T., Larghi, P., Pasqualini, F., Nebuloni, M., Chen, I.H., et al. Divergent effects of hypoxia on dendritic cell functions. Blood 112 (2008), 3723–3734.
111. Nombela-Arrieta, C., Ritz, J., Silberstein, L.E., The elusive nature and function of mesenchymal stem cells. Nat. Rev. Mol. Cell Biol. 12 (2011), 126–131.
112. Wang, M., Yuan, Q., Xie, L., Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int., 2018, 2018, 3057624.
113. Sapoznikov, A., Pewzner-Jung, Y., Kalchenko, V., Krauthgamer, R., Shachar, I., Jung, S., Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat. Immunol. 9 (2008), 388–395.
114. Dokic, J., Tomic, S., Markovic, M., Milosavljevic, P., Colic, M., Mesenchymal stem cells from periapical lesions modulate differentiation and functional properties of monocyte-derived dendritic cells. Eur. J. Immunol. 43 (2013), 1862–1872.
115. Chen, Q., Shou, P., Zheng, C., Jiang, M., Cao, G., Yang, Q., et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts?. Cell Death Differ. 23 (2016), 1128–1139.
116. Silva, A.M., Almeida, M.I., Teixeira, J.H., Maia, A.F., Calin, G.A., Barbosa, M.A., et al. Dendritic cell-derived extracellular vesicles mediate mesenchymal Stem/Stromal cell recruitment. Sci. Rep., 7, 2017, 1667.
117. Wang, W., Li, P., Li, W., Jiang, J., Cui, Y., Li, S., et al. Osteopontin activates mesenchymal stem cells to repair skin wound. PLoS One, 12, 2017, e0185346.
118. Wang, Y., Chen, X., Cao, W., Shi, Y., Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15 (2014), 1009–1016.
119. de Girolamo, L., Lucarelli, E., Alessandri, G., Avanzini, M.A., Bernardo, M.E., Biagi, E., et al. Mesenchymal stem/stromal cells: a new’ ’cells as drugs’’ paradigm. Efficacy and critical aspects in cell therapy. Curr. Pharm. Des. 19 (2013), 2459–2473.
120. Rustad, K.C., Gurtner, G.C., Mesenchymal stem cells home to sites of injury and inflammation. Adv. Wound Care (New Rochelle) 1 (2012), 147–152.
121. Spaggiari, G.M., Moretta, L., Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol. Cell Biol. 91 (2013), 27–31.
122. Torres, R., Herrerias, A., Serra-Pages, M., Marco, A., Plaza, J., Costa-Farre, C., et al. Locally administered prostaglandin E2 prevents aeroallergen-induced airway sensitization in mice through immunomodulatory mechanisms. Pharmacol. Res. 70 (2013), 50–59.
123. Royce, S.G., Rele, S., Broughton, B.R.S., Kelly, K., Samuel, C.S., Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease. Faseb J. 31 (2017), 4168–4178.
124. Boumans, M.J., Houbiers, J.G., Verschueren, P., Ishikura, H., Westhovens, R., Brouwer, E., et al. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann. Rheum. Dis. 71 (2012), 180–185.
125. West, C.E., Kvistgaard, A.S., Peerson, J.M., Donovan, S.M., Peng, Y.M., Lonnerdal, B., Effects of osteopontin-enriched formula on lymphocyte subsets in the first 6 months of life: a randomized controlled trial. Pediatr. Res. 82 (2017), 63–71.
126. Clemente, N., Comi, C., Raineri, D., Cappellano, G., Vecchio, D., Orilieri, E., et al. Role of anti-osteopontin antibodies in multiple sclerosis and experimental autoimmune encephalomyelitis. Front. Immunol., 8, 2017, 321.
127. Kaleta, B., The role of osteopontin in kidney diseases. Inflamm. Res. 68 (2019), 93–102.
128. Wang, L.T., Ting, C.H., Yen, M.L., Liu, K.J., Sytwu, H.K., Wu, K.K., et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials. J. Biomed. Sci., 23, 2016, 76.
129. Bernardo, M.E., Fibbe, W.E., Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann. N. Y. Acad. Sci. 1266 (2012), 107–117.
130. Chen, K., Liu, Q., Tsang, L.L., Ye, Q., Chan, H.C., Sun, Y., et al. Human MSCs promotes colorectal cancer epithelial-mesenchymal transition and progression via CCL5/beta-catenin/Slug pathway. Cell Death Dis., 8, 2017, e2819.